PharmaShots Weekly Snapshots (July 19 – 23, 2021)

 PharmaShots Weekly Snapshots (July 19 – 23, 2021)

AstraZeneca’s Bydureon BCise (exenatide extended-release) Receives the US FDA’s Approval for the Treatment of Type2 Diabetes

Published: July 23, 2021 | Tags: AstraZeneca, Bydureon BCise, exenatide extended-release, US, FDA, Approval, Type2 Diabetes

ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Boehringer Ingelheim for CD8 ImmunoPET Technology

Published: July 23, 2021 | Tags: ImaginAb, Non-Exclusive License Agreement, Boehringer Ingelheim, CD8 ImmunoPET Technology

Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115, Proposed Biosimilar to Ustekinumab

Published: July 23, 2021 | Tags: Meiji, Dong-A ST, Intas, Commercialize, DMB-3115, Ustekinumab

Celltrion Collaborates with Inhalon to Develop Regdanvimab (CT-P59) for the Treatment of COVID-19 at Home

Published: July 23, 2021 | Tags: Celltrion, Inhalon, Regdanvimab, CT-P59, COVID-19

NGM Reports Completion of Patient Enrollment in P-II CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Published: July 23, 2021 | Tags: NGM, P-II, CATALINA Study, NGM621, Geographic Atrophy, Age-Related Macular Degeneration

Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies

Published: July 23, 2021 | Tags: Synaffix, License Agreement, ProfoundBio, ADC Technologies

Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA’s Approval for the Treatment of Advanced Endometrial Carcinoma

Published: July 22, 2021 | Tags: Merck, Eisai, Keytruda, pembrolizumab, Lenvima, Lenvatinib, US, FDA, Approval, Advanced Endometrial Carcinoma

Bluebird Bio’s Skysona (elivaldogene autotemcel) Receives EC’s Approval for the Treatment of Cerebral Adrenoleukodystrophy

Published: July 22, 2021 | Tags: bluebird bio, Skysona, elivaldogene autotemcel, Lenti-D, EC, Approval, Cerebral Adrenoleukodystrophy

Mabpharm’s Biobetter (CMAB008) for Infliximab Receives NMPA’s Approval in China

Published: July 22, 2021 | Tags: Sorrento, Mabpharm, Infliximab Biobetter, Marketing Approval, China

IM Reports Results of IMT-002 in P-Ib MAD Trial for the Treatment of Type 1 Diabetes

Published: July 22, 2021 | Tags: IM, IMT-002, P-Ib, MAD Trial, Type 1 Diabetes, T1D

Bayer and Merck’s Verquvo (vericiguat) Receives the EC’s Approval for the Treatment of Chronic Heart Failure

Published: July 22, 2021 | Tags: Bayer, Merck, Verquvo, vericiguat, EC, Approval, Chronic Heart Failure

Lexeo Acquires Stelios to Expands its Gene Therapy Pipeline for Rare Cardiovascular Diseases

Published: July 22, 2021 | Tags: Lexeo, Stelios, Gene Therapy Pipeline, Programs, Rare Cardiovascular Diseases

Calliditas Signs a License Agreement with STADA to Commercialize Specialty Therapy for the Treatment of IgA Nephropathy in EU

Published: July 21, 2021 | Tags: Calliditas, STADA, Commercialize, Specialty Therapy, Chronic Autoimmune Kidney Disease IgAN, EU

Genentech’s Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes

Published: July 21, 2021 | Tags: Genentech, Venclexta, venetoclax, Azacitidine, Breakthrough Therapy Designation, Myelodysplastic Syndromes

Scilex Reports Completion of Patient Enrollment in P-III C.L.E.A.R. Program for Semdexa (SP-102) to Treat Sciatica Pain Management

Published: July 21, 2021 | Tags: Scilex, P-III, C.L.E.A.R. Program, Semdexa, SP-102, Sciatica Pain Management

Albireo’s Bylvay (odevixibat) Receives the US FDA’s Approval for the Treatment of Progressive Familial Intrahepatic Cholestasis

Published: July 21, 2021 | Tags: Albireo, Bylvay, odevixibat, US, FDA, Approval, Progressive Familial Intrahepatic Cholestasis

Relmada In-Licenses Psilocybin Program from Arbormentis

Published: July 21, 2021 | Tags: Relmada, In Licenses, Psilocybin Program, Arbormentis

Merck Presents Results from P-IIa Clinical Trial of Islatravir (MK-8591) for the Prevention of HIV at IAS 2021

Published: July 21, 2021 | Tags: Merck, Islatravir, MK-8591, P-IIa, Clinical Trial, HIV, IAS 2021

Myovant’s Ryeqo (relugolix, estradiol, and norethindrone acetate) Receives EC’s Approval for the Treatment of Women with Uterine Fibroids

Published: July 20, 2021 | Tags: Myovant, Ryeqo, relugolix, estradiol, norethindrone acetate, EC, Approval, Uterine Fibroids

BioNTech Signs a Purchase Agreement to Acquire Kite’s Cell Therapy, R&D Platform and Manufacturing Facility in Gaithersburg, MD

Published: July 20, 2021 | Tags: BioNTech, Kite, Cell Therapy, R&D Platform, Manufacturing Facility, Gaithersburg, MD

Kadmon’s Rezurock (belumosudil) Receives the US FDA’s Approval for the Treatment of Chronic Graft Versus Host Disease

Published: July 20, 2021 | Tags: Kadmon, Rezurock, belumosudil, US, FDA, Approval, Chronic Graft Versus Host Disease

Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Published: July 20, 2021 | Tags: Samsung Bioepis, P-III, Clinical Trial, SB17, Proposed Biosimilar, Stelara, ustekinumab

Regeneron’s Ronapreve Antibody Cocktail (casirivimab and imdevimab) Receives MHLW’s Approval for the Treatment of Mild to Moderate COVID-19

Published: July 20, 2021 | Tags: Regeneron, REGEN-COV Antibody Cocktail, casirivimab, imdevimab, MHLW, Approval, COVID-19

AstraZeneca Signs an Exclusive WW License Agreement with Aridis for Suvratoxumab to Prevent Pneumonia

Published: July 20, 2021 | Tags: AstraZeneca, License Agreement, Aridis, Suvratoxumab, Pneumonia

Genentech Reports New Data of Hemlibra (emicizumab-kxwh) in P-IIIb STASEY Study to Treat Hemophilia A

Published: July 19, 2021 | Tags: Genentech, Hemlibra, emicizumab-kxwh, P-IIIb, STASEY Study, Hemophilia A

Gilead Reports New Data of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV

Published: July 19, 2021 | Tags: Gilead, Lenacapavir, P-II/III, CAPELLA Trial, HIV

AstraZeneca’s Imfinzi (durvalumab) Receives NMPA’s Approval as a 1L Treatment of Extensive-Stage Small Cell Lung Cancer

Published: July 19, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab, NMPA, Approval, Extensive-Stage Small Cell Lung Cancer

Sanofi’s Fexinidazole Receives the US FDA’s Approval as the First Oral Treatment for Sleeping Sickness

Published: July 19, 2021 | Tags: Sanofi, Fexinidazole, US, FDA, Approval, Sleeping Sickness

Merck’s Vaxneuvance (pneumococcal 15-valent conjugate vaccine) Receives the US FDA’s Approval for the Prevention of Invasive Pneumococcal Disease Caused by 15 Serotypes

Published: July 19, 2021 | Tags: Merck, Vaxneuvance, Pneumococcal 15-valent Conjugate Vaccine, US, FDA, Approval, Invasive Pneumococcal Disease, 15 Serotypes

GSK Reports Results of Daprodustat in P-III ASCEND Program for the Treatment of Anemia due to Chronic Kidney Disease

Published: July 19, 2021 | Tags: GSK, Daprodustat, Five, P-III, Studies, Anaemia, Chronic Kidney Disease

Related Post: PharmaShots Weekly Snapshots (July 12 – 16, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post